Tuberc Respir Dis Search

CLOSE


Tuberc Respir Dis > Volume 76(4); 2014 > Article
Park, Lee, Seo, Hong, Yoo, Kang, Lee, Oh, Lee, and KOLD Study Group: Study Design and Outcomes of Korean Obstructive Lung Disease (KOLD) Cohort Study

Abstract

Background

The Korean Obstructive Lung Disease (KOLD) Cohort Study is a prospective longitudinal study of patients with chronic obstructive pulmonary disease (COPD), asthma, or other unclassified obstructive lung diseases. It was designed to develop new classification models and biomarkers that predict clinically relevant outcomes for patients with obstructive lung diseases.

Methods

Patients over 18 years old who have chronic respiratory symptoms and airflow limitations or bronchial hyper-responsiveness were enrolled at 17 centers in South Korea. After a baseline visit, the subjects were followed up every 3 months for various assessments.

Results

From June 2005 to October 2013, a total of 477 subjects (433 [91%] males; 381 [80%] diagnosed with COPD) were enrolled. Analyses of the KOLD Cohort Study identified distinct phenotypes in patients with COPD, and predictors of therapeutic responses and exacerbations as well as the factors related to pulmonary hypertension in COPD. In addition, several genotypes were associated with radiological phenotypes and therapeutic responses among Korean COPD patients.

Conclusion

The KOLD Cohort Study is one of the leading long-term prospective longitudinal studies investigating heterogeneity of the COPD and is expected to provide new insights for pathogenesis and the long-term progression of COPD.

Introduction

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide and is associated with substantial socioeconomic burdens which are increasing continuously in many countries1. The situation seems particularly serious in Asia because of the high prevalence of tobacco smoking, exposure to outdoor and indoor air pollution related to the burning of wood and other biomass fuels, and exposure to occupational dust2. The fourth Korean National Health and Nutrition Examination Survey conducted in Korea revealed that the prevalence of COPD in subjects aged >40 years was 13.4%. However, only a minority of COPD patients still receive physician's diagnosis or treatment not only in its early stages but even when lung function is severely impaired3.
One of the main reasons for under-diagnosis and under-treatment of COPD is that the disease progresses slowly and is heterogeneous. Although chronic airflow limitation is one important characteristic of COPD, the disease shows heterogeneous features in terms of clinical presentation, physiology, imaging, response to therapy, decline in lung function, and survival, even in patients that show a similar degree of airflow limitation4. This heterogeneity might arise from differences in environmental factors and/or the patient's genetic background. It follows, therefore, that long-term observational cohort studies should be performed in different countries, or regions in which patients of different genetic backgrounds may have been exposed to different disease etiologies to identify the pathogenesis of COPD heterogeneity.
Asia is a very heterogeneous region containing many countries at various stages of development and of varying socioeconomic status. While several cohort studies of COPD are ongoing in Western countries5,6, a few longitudinal studies are being conducted in Asia7. Thus, in terms of ethnic heterogeneity, there is a need to activate longitudinal studies of COPD patients across Asia.
The Korean Obstructive Lung Disease (KOLD) Cohort Study is an ongoing prospective longitudinal study that includes patients with COPD, asthma, or other unclassified obstructive lung disease. The aims of the KOLD Cohort Study were to provide a new disease classification of obstructive lung disease, and to identify interactive prognostic factors for obstructive lung disease. The present article describes the design and interim results of the KOLD Cohort Study.

Materials and Methods

1. Study design

Seventeen centers in South Korea participated in the study. Eleven centers joined in June 2005, and another 6 centers have joined since 2010. Patient screening was based on demographic data, medical history, physical examination, spirometry and a methacholine bronchial provocation test (if forced expiratory volume in 1 second [FEV1] >60% predicted). After an initial enrollment visit, initial outcome measurements were taken and the patients were followed up every 3 months. In addition to regular follow-ups, emergency visits were carried out and outcome measurements were taken when patients experienced exacerbations. The present study was approved by the institutional review board of the Asan Medical Center Institutional Review Board (No. 2005-0345) and by the Institutional Review Boards of the other 16 hospitals taking part. Written informed consent was obtained from all patients.

2. Subjects

The inclusion criteria for the KOLD Cohort Study were patients over 18 years-of-age with chronic respiratory symptoms as well as one or both of the criteria, airflow limitation or bronchial hyper-responsiveness. "Chronic" was defined as symptoms lasting for more than 3 months, or repeated symptoms experienced at intervals of more than 3 months. Respiratory symptoms were defined as dyspnea, cough, wheeze, or sputum production. Airflow limitation was defined as a pre-bronchodilator FEV1 over forced vital capacity (FVC) value of less than 0.7 (FEV1/FVC<0.7). Bronchial hyper-responsiveness was measured using the methacholine provocation test, and was defined as the provocative concentration that reduces the FEV1 by 20% below 16 mg/mL (provocative concentration that reduces the FEV1 by 20% [PC20]≤16 mg/mL). Unlike other studies, the KOLD Cohort Study did not use smoking history as an inclusion criterion. In addition, patients with bronchial hyper-responsiveness were included. Furthermore, a pre-bronchodilator FEV1/FVC<0.7 was used rather than post-bronchodilator FEV1/FVC<0.7 to allow the inclusion of asthma and other unclassified obstructive lung disease patients in the study.
Exclusion criteria were patients with co-existing illnesses that would interfere with the study results (e.g., malignancy, congestive heart failure, cerebrovascular disorders, chronic renal failure, diabetes with severe complications, and uncontrolled hypertension), and respiratory diseases other than obstructive lung disease (e.g., previous pulmonary resection, tuberculosis-destroyed lung, and bronchiectasis). Patients with a recent (8 weeks before screening) exacerbation or other respiratory illness (such as upper respiratory infection or pneumonia) were also excluded. However, patients who recovered from an exacerbation and had been stable for more than 8 weeks were included in the study.

3. Outcome measurement

The evaluation of the KOLD Cohort Study patients is described in Table 1, along with the measurement intervals. The outcome measurements included clinical, pulmonary functional, radiological, genetic outcomes. The clinical outcomes measured were dyspnea (assessed using the modified UK Medical Research Council [MRC] dyspnea scale), exacerbations, patient-reported health outcomes (e.g., Saint George's Respiratory Questionnaire or COPD Assessment Test), psychological status (depression and anxiety score), sexual function, and comorbidities. Measurements of pulmonary function included spirometry (pre- and post-bronchodilator test), lung volume (body plethysmography) and diffusing capacity for carbon monoxide (single-breath method). Because FEV1 is the defining characteristic of obstructive lung disease, all patients performed a spirometry test at follow-up when possible. Upon enrollment, after 1 year, and then at intervals of 3 years, volumetric computed tomography (CT) scans were taken at full inspiration and expiration using 16-multidetector CT scanners produced by three different manufacturers (Somatom Sensation 16; Siemens Medical Systems, Bonn, Germany; GE Lightspeed Ultra; General Electric Healthcare, Milwaukee, WI, USA; and Philips Brilliance 16, Philips Medical Systems, Best, Netherlands). Images of the whole lung were extracted automatically and the attenuation coefficient of each pixel was calculated. Emphysema index (volume fraction of the lung<-950 HU), air trapping index (mean lung density at full expiration over mean lung density at full inspiration), and airway thickening (wall area percentage of two segmental bronchi; RB1 and LB1+2) were used for quantitative assessment using CT. Serum, plasma, DNA and urine samples were collected for biomarker and genetic/proteomic analysis. Other outcome measurements included body composition (measure using whole body impedance), resting oxygen saturation, the 6-minute walk test, airway resistance (measured using impulse oscillometry), and trans-thoracic echocardiography.

Results

From May 2005 to October 2013, a total of 477 subjects were enrolled. All patients were over the age of 40 years (mean age, 66.1±7.9 years). Of these, 433 (91%) were male, 403 (84%) had a smoking history more than 10 pack-years (mean smoking history, 46.3±27.3 pack-years), and 381 (80%) were diagnosed with COPD according to the presence of an airflow limitation that was not fully reversible (post-bronchodilator FEV1/FVC<0.7) and a smoking history of more than 10 pack-years. To date, 39 (8%) patients have died during follow-up, 110 (23%) ended follow-up in early stages, and 328 (69%) are still being followed-up.
The interim analyses of the KOLD Cohort Study identified various predictors of therapeutic response8,9,10,11. These include clinical, pulmonary functional, radiological or combined factors. Genotypes, such as the ADRB2 or CRHR1 gene polymorphisms, were also associated with therapeutic response12,13. The majority of the analyses addressed therapeutic response in lung function to inhaled bronchodilators, either with or without corticosteroids. Combination of clinical and lung function indices was better at predicting acute exacerbations than radiological factors14. Radiological assessments made using volumetric CT correlated with clinically meaningful outcomes, such as the BODE index and its components15. Volumetric CT was able to quantitatively assess the regional heterogeneity of emphysema, and showed pulmonary function test values were more influenced by the severity of emphysema in the lower lungs than the severity of emphysema in the upper lungs16. The ADRB2 gene polymorphism was associated with airway wall phenotypes as measured by CT, suggesting that it may be one of the determining factors of the radiological COPD phenotype17. In addition, cluster analysis identified distinct phenotypes in elderly with obstructive lung disease and factors related to pulmonary hypertension in COPD patients18,19. Furthermore, combining the analysis of KOLD with that of the Cohort for Reality and Evolution of Adult Asthma in Korea (COREA) has identified and characterized an overlap syndrome, which is an intermediate between asthma and COPD in clinical characteristics20.

Discussion

COPD is a heterogeneous disease that may have different etiologies, pathogenesis, and host responses. A particular COPD phenotype may be related to a distinct natural history and respond differently to treatment. Discovering new COPD phenotypes involves identifying patient groups with unique prognostic or therapeutic characteristics. Originally the term "phenotype" referred to the composite of the observable characteristics or traits of an organism. However, a more concise definition of COPD phenotypes is needed to supersede the currently used descriptions, "blue bloater" and "pink puffer." Recently, a new definition of the COPD phenotype was suggested as follows: a single or combination of disease attributes that describe difference between individuals with COPD that relate to clinically meaningful outcomes (symptoms, exacerbations, response to therapy, rate of disease progression, or death)4. This definition will help to identify the clinically relevant COPD phenotypes.
The 8-year prospective study conducted by Fletcher et al.21 (The Natural History of Chronic Bronchitis and Emphysema, published in 1976) is still the most highly cited summary of COPD natural history. However, it focused primarily on FEV1 and did not address the natural history of other features of COPD. In addition, the duration of the study was relatively short compared with the natural history of COPD. Because COPD progresses slowly, the heterogeneity of COPD natural history can only be determined by prospective longitudinal studies for longer duration22.
Recent studies suggest that there are racial differences in terms of COPD susceptibility, treatment, and prognosis23,24,25. Most of these studies looked at the higher susceptibility of African Americans race to tobacco smoke compared with that of Caucasians. This implies that racial differences also exist in Asians. In addition to racial differences in susceptibility to COPD, a growing number of studies have identified COPD risk factors that are not related to smoking. These risk factors include exposure to indoor and outdoor pollutants, workplace exposure to dust and fumes, a history of repeated lower respiratory-tract infections during childhood, a history of pulmonary tuberculosis or, chronic asthma, intrauterine growth retardation, poor nourishment, and poor socioeconomic status26. These risks are particularly relevant to non-smoking Asian females. However, it is not clear whether COPD phenotype in non-smokers is different from that in smokers. Therefore, ethnic heterogeneity and risk factors for COPD in non-smoker are points that should be assessed in collaborative COPD research projects conducted across various Asian countries.
The KOLD Cohort Study used different inclusion criteria from those used in other longitudinal studies of COPD. First, the KOLD Cohort Study did not use smoking history as an indispensable inclusion criterion. Although most patients enrolled in the KOLD Cohort Study have smoking history more than 10 pack-years, we leave room to take non-smoker COPD patients. Second, a pre-bronchodilator FEV1/FVC<0.7 was used as an inclusion criterion to include patients with COPD as well as asthma and unclassified obstructive lung disease. Third, the KOLD Cohort Study used bronchial hyper-responsiveness as an inclusion criterion. Bronchial hyper-responsiveness is an important predictor of an accelerated decline in FEV1 and is thought to be second only to cigarette smoking as a significant risk factor for COPD27,28. This flexibility of inclusion criteria used in the KOLD Cohort Study would facilitate to dissect heterogeneity of obstructive lung disease.
As radiologic characterization of COPD with volumetric CT, the low attenuation area and segmental wall area percentage or thickness are used mostly. These indices are associated with various clinical outcomes of COPD29. In addition, the KOLD Cohort Study used CT air trapping index as small airway obstruction index. This index, as well as the emphysema index and the segmental wall area percentage, was independently correlated with various clinical parameters of COPD11,15.
A better understanding of COPD heterogeneity requires multinational collaborative research. Thus, the Asian Network for Obstructive Lung Disease (ANOLD) has been built as an extension of the KOLD Cohort Study30. In the ANOLD, researchers from 12 regions of Asia have participated and recruited more than 1,000 COPD patients since September 2009. The purpose of the ANOLD is to characterize COPD heterogeneity in Asia by determining the relationship between clinical outcomes and various aspects of the disease. A new insight into the pathogenesis and long-term natural history of COPD could be achieved through collaborative research conducted in various Asian countries. Undertaking longitudinal studies for longer duration in Asian COPD patients would enable to discover distinct COPD phenotypes with new therapeutic and prognostic biomarkers.
In conclusion, the KOLD Cohort Study is one of the leading long-term prospective longitudinal studies investigating the heterogeneity of COPD in Asia. Furthermore, in conjunction with the ANOLD, the KOLD Cohort Study is expected to provide new insights into the pathogenesis and long-term progression of COPD.

Acknowledgements

The authors thank the members of the Korean Obstructive Lung Disease (KOLD) Cohort Study Group: Prof. Sang-Do Lee, Prof. Yeon-Mok Oh, Prof. Joon Beom Seo, Moo Song Lee, Prof. Jin Won Huh, Prof. Seung Won Ra, Prof. Jae Seung Lee, Prof. Sei Won Lee, Prof. Eun Jin Chae, Prof. Nam Kug Kim (Univ. of Ulsan), Prof. Deog Kyeom Kim, Prof. Sang-Min Lee, Prof. Ho Il Yoon (Seoul National Univ.), Prof. Tae-Hyung Kim, Prof. Sang-Heon Kim (Hanyang Univ.), Prof. Young Sam Kim (Yonsei Univ.), Prof. Woo Jin Kim (Kangwon National Univ.), Prof. Hye Kyeong Park, Prof. Sung-Soon Lee (Inje Univ.), Prof. Ji-Hyun Lee, Eun Kyung Kim (Bundang CHA Hospital), Prof. Jin Hwa Lee (Ewha Womans Univ.), Prof. Sang Yeub Lee (Korea Univ.), Prof. Seong Yong Lim (Sungkyunkwan Univ.), Prof. Tae Rim Shin, Yong Il Hwang (Hallym Univ.), Prof. Seung Soo Sheen (Ajou Univ.), Prof. Prof. Kwang Ha Yoo (Konkuk Univ.), Prof. Chin Kook Rhee (Catholic Univ.), and Prof. Young Kyung Lee (Kyung Hee Univ.).
This study was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (A102065).

Notes

The abstract was submitted and was presented at the "Airway Vista 2013" which was held on 29-31 Mar 2013 at Asan Medical Center, Seoul, Korea.

Tai Sun Park, Jae Seung Lee, Yoonki Hong, Jung-Wan Yoo, Byung Ju Kang and Sei Won Lee have no conflicts of interest to disclose. Joon Beom Seo has been an investigator in a government-sponsored study (2006-2008 Korea Science and Engineering Foundation). Yeon-Mok Oh (YMO) has been an investigator in industry-sponsored studies (MSD Korea, AstraZeneca Korea, BoehringerIngelheim Korea, Handok and GlaxoSmithKline) and in university-sponsored studies (Asan Institute for Life Science, University of Ulsan College of Medicine). YMO has participated as a speaker at scientific meetings organized and financed by pharmaceutical companies (Handok, Pfizer Korea, GlaxoSmithKline, AstraZeneca Korea, MSD Korea, and Boehringer Ingelheim Korea) and a magazine company (Korea Doctors' Weekly). YMO developed an educational presentation for a pharmaceutical company (Diachi Sankyo Korea). Sang-Do Lee serves as a consultant to GlaxoSmithKline and Nycomed, and has participated as a speaker at scientific meetings organized and financed by various pharmaceutical companies (GlaxoSmithKline, AstraZeneca Korea, Nycomed and Boehringer Ingelheim).

References

1. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006;27:397-412. PMID: 16452599.
crossref pmid
2. Liu S, Zhou Y, Wang X, Wang D, Lu J, Zheng J, et al. Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China. Thorax 2007;62:889-897. PMID: 17483137.
crossref pmid pmc
3. Yoo KH, Kim YS, Sheen SS, Park JH, Hwang YI, Kim SH, et al. Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008. Respirology 2011;16:659-665. PMID: 21342331.
crossref pmid
4. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010;182:598-604. PMID: 20522794.
crossref pmid pmc
5. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010;11:122PMID: 20831787.
crossref pmid pmc
6. Kim V, Han MK, Vance GB, Make BJ, Newell JD, Hokanson JE, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest 2011;140:626-633. PMID: 21474571.
crossref pmid pmc
7. Nishimura M, Makita H, Nagai K, Konno S, Nasuhara Y, Hasegawa M, et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185:44-52. PMID: 22016444.
crossref pmid
8. Lee JH, Lee YK, Kim EK, Kim TH, Huh JW, Kim WJ, et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir Med 2010;104:542-549. PMID: 19926461.
crossref pmid
9. Lee JS, Huh JW, Chae EJ, Seo JB, Ra SW, Lee JH, et al. Predictors of pulmonary function response to treatment with salmeterol/fluticasone in patients with chronic obstructive pulmonary disease. J Korean Med Sci 2011;26:379-385. PMID: 21394306.
crossref pmid pmc
10. Lee JS, Huh JW, Chae EJ, Seo JB, Ra SW, Lee JH, et al. Different therapeutic responses in chronic obstructive pulmonary disease subgroups. Int J Tuberc Lung Dis 2011;15:1104-1110. PMID: 21740676.
crossref pmid
11. Lee JS, Huh JW, Chae EJ, Seo JB, Ra SW, Lee JH, et al. Response patterns to bronchodilator and quantitative computed tomography in chronic obstructive pulmonary disease. Clin Physiol Funct Imaging 2012;32:12-18. PMID: 22152074.
crossref pmid
12. Kim WJ, Oh YM, Sung J, Kim TH, Huh JW, Jung H, et al. Lung function response to 12-week treatment with combined inhalation of long-acting beta2 agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease. Lung 2008;186:381-386. PMID: 18758858.
crossref pmid pdf
13. Kim WJ, Sheen SS, Kim TH, Huh JW, Lee JH, Kim EK, et al. Association between CRHR1 polymorphism and improved lung function in response to inhaled corticosteroid in patients with COPD. Respirology 2009;14:260-263. PMID: 19210659.
crossref pmid
14. Yoo JW, Hong Y, Seo JB, Chae EJ, Ra SW, Lee JH, et al. Comparison of clinico-physiologic and CT imaging risk factors for COPD exacerbation. J Korean Med Sci 2011;26:1606-1612. PMID: 22147998.
crossref
15. Lee YK, Oh YM, Lee JH, Kim EK, Lee JH, Kim N, et al. Quantitative assessment of emphysema, air trapping, and airway thickening on computed tomography. Lung 2008;186:157-165. PMID: 18351420.
crossref pmid pdf
16. Chae EJ, Seo JB, Song JW, Kim N, Park BW, Lee YK, et al. Slope of emphysema index: an objective descriptor of regional heterogeneity of emphysema and an independent determinant of pulmonary function. AJR Am J Roentgenol 2010;194:W248-W255. PMID: 20173123.
crossref pmid
17. Kim WJ, Oh YM, Sung J, Lee YK, Seo JB, Kim N, et al. CT scanning-based phenotypes vary with ADRB2 polymorphisms in chronic obstructive pulmonary disease. Respir Med 2009;103:98-103. PMID: 18789663.
crossref pmid
18. Jo KW, Ra SW, Chae EJ, Seo JB, Kim NK, Lee JH, et al. Three phenotypes of obstructive lung disease in the elderly. Int J Tuberc Lung Dis 2010;14:1481-1488. PMID: 20937191.
pmid
19. Lee JH, Oh YM, Seo JB, Lee YK, Kim WJ, Sheen SS, et al. Pulmonary artery pressure in chronic obstructive pulmonary disease without resting hypoxaemia. Int J Tuberc Lung Dis 2011;15:830-837. PMID: 21575307.
crossref pmid
20. Kim TB, Oh YM, Chang YS, Cho YS, Jang AS, Cho SH, et al. The reality of an intermediate type between asthma and COPD in practice. Respir Care 2012;57:1248-1253. PMID: 22348544.
crossref pmid
21. Fletcher C, Peto R, Tinker C, Speizer FE. The natural history of chronic bronchitis and emphysema: an eight-year study of early chronic obstructive lung disease in working men in London. New York: Oxford University Press; 1976.

22. Rennard SI, Vestbo J. Natural histories of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008;5:878-883. PMID: 19056710.
crossref
23. Foreman MG, Zhang L, Murphy J, Hansel NN, Make B, Hokanson JE, et al. Early-onset chronic obstructive pulmonary disease is associated with female sex, maternal factors, and African American race in the COPDGene Study. Am J Respir Crit Care Med 2011;184:414-420. PMID: 21562134.
crossref pmid pmc
24. Kirkpatrick dP, Dransfield MT. Racial and sex differences in chronic obstructive pulmonary disease susceptibility, diagnosis, and treatment. Curr Opin Pulm Med 2009;15:100-104. PMID: 19532023.
crossref pmid
25. Dransfield MT, Bailey WC. COPD: racial disparities in susceptibility, treatment, and outcomes. Clin Chest Med 2006;27:463-471. PMID: 16880056.
crossref pmid
26. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009;374:733-743. PMID: 19716966.
crossref
27. Brutsche MH, Downs SH, Schindler C, Gerbase MW, Schwartz J, Frey M, et al. Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort study. Thorax 2006;61:671-677. PMID: 16670173.
crossref pmid pmc
28. de Marco R, Accordini S, Marcon A, Cerveri I, Anto JM, Gislason T, et al. Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. Am J Respir Crit Care Med 2011;183:891-897. PMID: 20935112.
crossref pmid
29. Han MK, Bartholmai B, Liu LX, Murray S, Curtis JL, Sciurba FC, et al. Clinical significance of radiologic characterizations in COPD. COPD 2009;6:459-467. PMID: 19938970.
crossref
30. ANOLD, Asian Network for Obstructive Lung Disease [Internet]. Seoul: ANOLD Coordination center; cited 2013 Oct 11. Available from: http://www.anold.org/.

Table 1
Evaluations of the Korean Obstructive Lung Disease Cohort Study patients
trd-76-169-i001.jpg

●: required; ◐: optional; ○: performed 3 months after enrollment, then again 1 year later; ◎: performed 1 year after enrollment, then again 3 years later.

*Only males. Charlson's score. Performed if FEV1>60% predicted.

MRC: UK Medical Research Council; CAT: Chronic Obstructive Pulmonary Disease Assessment Test; AE: acute exacerbation; SGRQ: Saint George's Respiratory Questionnaire; BDI: Beck Depression Inventory; BAI; Beck Anxiety Inventory; IIEF-5: The International Index of Erectile Function Questionnaire; BDR: bronchodilator response; MBPT: methacholine bronchial provocation test; PA: posterior-anterior; CT: computed tomography; CBC: complete blood count; CRP: C-reactive protein; BNP: brain natriuretic peptide; ECG: electrocardiography.



ABOUT
ARTICLE & TOPICS
Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES
FOR CONTRIBUTORS
Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail: katrdsubmit@lungkorea.org                

Copyright © 2021 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next